Moderna Inc. ($MRNA) Stock Forecast: Down 10.7% Today

What is Moderna Inc.?

A biotechnology company recognized for its mRNA-based vaccines, Moderna (MRNA) saw a downtrend in its stock amidst market fluctuations.

Why is Moderna Inc. going down?

MRNA stock is down 10.7% on Jan 23, 2026 19:35

• The stock's decline could be attributed to profit-taking or concerns about vaccine distribution challenges.
• Positive updates on Lucid Group, Materion Corp, and Terns Pharmaceuticals might have shifted investor focus away from Moderna.
• Other companies' positive news and Itaú Unibanco's upcoming investor meeting could have added to the downward pressure on Moderna's stock.
• Despite today's bearish movement, Moderna's long-term outlook remains optimistic due to its crucial role in the pandemic response and continuous vaccine innovations.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Why Did Lucid Stock Soar This Week?

Lucid Group's stock surged 12% this week, driven by news of its expanding manufacturing facility in Saudi Arabia. The investment by Saudi Arabia's Public Investment Fund (PIF), which owns 60% of Lucid, provided critical financial backing and confidence to investors. Industrial automation giant Rockwell Automation is partnering with Lucid to enhance production operations at the Saudi plant, further solidifying PIF's long-term commitment to the EV maker.

https://finviz.com/news/285623/why-did-lucid-stock-soar-this-week

Materion Corp stock hits all-time high at 151.41 USD By Investing.com

Materion Corp (MTRN) stock reached an all-time high of $151.41, surpassing its previous 52-week high, with a 48.11% appreciation over the past year. Despite its high P/E ratio and overvalued status, the company has maintained dividend payments for 14 consecutive years. Recent developments include a slight beat on Q3 2025 earnings, a downgrade by KeyBanc citing demand uncertainty, and board changes with N. Mohan Reddy retiring and Thomas Edman joining.

https://ng.investing.com/news/company-news/materion-corp-stock-hits-alltime-high-at-15141-usd-93CH-2301488

Laser Photonics secures $1.3 million order from new pharma customer By Investing.com

Laser Photonics Corporation announced a $1.3 million order for a pharmaceutical tablet laser drilling system from a new international pharmaceutical customer. This order, for a custom TD-140 system, is significant for the small-cap company which has faced a nearly 59% stock price decline over the past year. Despite recent revenue growth, the company faces financial challenges, with short-term obligations exceeding liquid assets.

https://ng.investing.com/news/company-news/laser-photonics-secures-13-million-order-from-new-pharma-customer-93CH-2301184

Terns Pharmaceuticals amends license agreement with Hansoh for TERN-701 rights

Terns Pharmaceuticals has amended its license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. for TERN-701, a therapeutic product for oncology indications. The new amendment grants Terns Pharmaceuticals exclusive worldwide rights, excluding the Hansoh Territory, to patents and applications related to TERN-701, replacing a previous non-exclusive license. Terns will pay a one-time upfront fee of $1 million and tiered royalties on net sales, reinforcing its strong financial position and recent positive clinical and financial developments.

https://www.investing.com/news/sec-filings/terns-pharmaceuticals-amends-license-agreement-with-hansoh-for-tern701-rights-93CH-4461404

Itaú Unibanco Calls Investor Meeting to Announce Q4 Results

Itaú Unibanco's stock (NYSE: ITUB) has seen a 4.2% increase, driven by positive market anticipation ahead of its Q4 investor meeting and increased government investments in Brazil. The meeting is expected to cover strategic initiatives and financial results, reinforcing investor confidence through transparent communication. The bank boasts strong financials with $158.568B in revenues and $2,854.475 trillion in assets, indicating a robust foundation for future growth.

https://www.timothysykes.com/news/itau-unibanco-banco-holding-sa-itub-news-2026_01_22/

Trending Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.1% Today

Ethereum ($ETH) Crypto Forecast: Down 5.2% Today

Shiba Inu ($SHIB) Crypto Forecast: Down 5.1% Today

XRP ($XRP) Crypto Forecast: Down 5.1% Today

Solana ($SOL) Crypto Forecast: Down 5.2% Today

Chainlink ($LINK) Crypto Forecast: Down 5.0% Today

Ziliqa ($ZIL) Crypto Forecast: Down 5.5% Today

Cardano ($ADA) Crypto Forecast: Down 5.0% Today

Monero ($XMR) Crypto Forecast: Down 5.4% Today

Moderna Inc. Price History

23.00.2026 - MRNA Stock was down 10.9%

• The stock's decline may have been driven by profit-taking by investors following a recent 4% rally linked to positive five-year follow-up data for their mRNA cancer vaccine in collaboration with Merck.
• Concerns about potential competition or market positioning for Moderna in the oncology sector could have arisen with the amendment of the license agreement between Terns Pharmaceuticals and Hansoh for TERN-701 rights.
• Investor focus and capital might have been redirected towards the banking sector, particularly awaiting Itaú Unibanco's Q4 results, contributing to Moderna's downward trend.
• Despite the promising long-term prospects in oncology, external factors and short-term market dynamics possibly influenced the bearish performance today.

23.00.2026 - MRNA Stock was down 9.4%

• Moderna's stock saw a strong bearish movement possibly due to the announcement of limiting investment in new late-stage vaccine trials, reflecting concerns over achieving returns amidst regulatory hurdles and opposition in the US market.
• The groundbreaking five-year follow-up data for their mRNA cancer vaccine, which demonstrated positive results in high-risk melanoma patients, might have been overshadowed by the decision to curb vaccine trial investments, leading to investor uncertainty.
• The amended license agreement with Hansoh for TERN-701 by Terns Pharmaceuticals could have also impacted Moderna's stock negatively, as it potentially shifts focus and resources away from certain therapeutic products.
• Overall, the market may be reacting to the shifting priorities and strategies within Moderna, as it navigates challenges in the regulatory landscape and transitions towards personalized cancer treatments, impacting investor sentiment and stock performance.

23.00.2026 - MRNA Stock was down 10.7%

• The stock's decline could be attributed to profit-taking or concerns about vaccine distribution challenges.
• Positive updates on Lucid Group, Materion Corp, and Terns Pharmaceuticals might have shifted investor focus away from Moderna.
• Other companies' positive news and Itaú Unibanco's upcoming investor meeting could have added to the downward pressure on Moderna's stock.
• Despite today's bearish movement, Moderna's long-term outlook remains optimistic due to its crucial role in the pandemic response and continuous vaccine innovations.

16.00.2026 - MRNA Stock was up 6.6%

• Moderna witnessed a significant surge in its stock performance recently.
• The notable uptick in the market's reaction is linked to Moderna's optimistic preliminary sales projection for 2025 and favorable business prospects for 2026 onwards. These projections involve updated forecasts for operating expenses, improved cash reserves, and anticipated milestones in its product pipeline, such as upcoming regulatory submissions for novel vaccines and advancements in personalized cancer treatments.
• Despite the projected decrease in revenue due to declining demand for COVID vaccines, Moderna's strategic announcements have bolstered investor confidence in its future growth trajectory.
• The recent invalidation of a patent owned by Arbutus Biopharma, a company engaged in legal disputes with Moderna, could have positively influenced Moderna's stock price by potentially resolving some legal uncertainties for Moderna in the European market.

16.00.2026 - MRNA Stock was up 6.1%

• Moderna's optimistic outlook today is linked to its increased full-year 2025 revenue guidance to $1.9 billion, demonstrating significant growth potential.
• The positive trajectory is supported by Moderna's cost-cutting initiatives, an enhanced cash balance projection, and the ongoing phase three melanoma trial identified as a key driver for 2026 by RBC Capital.
• The decline in Arbutus Biopharma's stock value, stemming from a patent dispute with Moderna, may have inadvertently influenced Moderna's upward trend as investors may view Moderna as solidifying its competitive standing in the biopharmaceutical sector.

21.00.2026 - MRNA Stock was up 16.9%

• Moderna's bullish movement today could be attributed to the broader positive sentiment in the cell and gene therapy market, driven by technological advancements and increasing demand for personalized medicine.
• Analysts' bullish outlook on Merck & Co. (MRK) and its potential acquisition of Revolution Medicines to strengthen its oncology pipeline may have positively influenced investor confidence in the biotech sector, including Moderna.
• The significant vaccine delivery licensing deal involving Pfizer and Novavax might have also boosted investor optimism in the biopharmaceutical industry, reflecting positively on Moderna's innovative approaches in vaccine development.
• Overall, the positive market movements in the biotech and pharmaceutical sectors, coupled with strategic advancements and collaborations within the industry, likely contributed to Moderna's strong bullish performance today.

21.00.2026 - MRNA Stock was up 5.5%

• Analysts are optimistic about Merck & Co. (MRK), with talk of a possible acquisition of Revolution Medicines enhancing positivity in the healthcare industry. This upbeat sentiment may have influenced the rise of Moderna's stock.
• The collaboration between Pfizer and Novavax on vaccine delivery technology showcases the competitive and ever-evolving landscape of the vaccine sector. This partnership potentially contributed to the favorable outlook towards Moderna.
• Moderna's strategic expansion into oncology, accompanied by encouraging data on its cancer therapy, has captured the attention of investors. The company's foray into areas beyond infectious disease vaccines might have played a part in its recent market upswing.
• Despite cautious views from BofA Securities on Moderna's stock value, the promising clinical results for its cancer vaccine Intismeran may have overshadowed apprehensions, leading to the positive momentum in the market.

21.00.2026 - MRNA Stock was up 11.6%

• The bullish movement in Moderna's stock today is influenced by the positive reception of the five-year follow-up data from its Phase IIb trial for a personalized mRNA-based cancer therapy, showing promising results for high-risk melanoma patients.
• Analyst sentiment toward Moderna remains optimistic, with BofA Securities recently raising its price target. Despite concerns about the stock valuation exceeding target levels and potential challenges in the oncology market, long-term confidence driven by strategic shifts and partnerships is boosting investor morale.
• Market movements within the biotechnology sector, such as news of acquisitions and licensing agreements by competitors like Merck and Novavax, may have also contributed to Moderna's positive momentum as investors recognize growth opportunities in the industry.
• Moderna's strategic focus on oncology, along with progress in its pipeline and favorable analyst outlook, positions the company well for future growth and innovation in the healthcare sector.

22.00.2026 - MRNA Stock was up 15.0%

• Moderna's bullish movement could be attributed to positive sentiment surrounding the company's COVID-19 vaccine sales and ongoing efforts in vaccine development.
• The market may be reacting favorably to the news of a global restructuring, potentially indicating investor confidence in companies adapting to optimize operations.
• Steady stock performance and positive outlook from an analyst firm could be contributing to a positive overall sentiment in the healthcare sector, benefiting companies like Moderna.
• A stock hitting a 52-week high and the positive analyst price target revisions could be boosting investor interest in the biotech sector, indirectly benefiting Moderna as well.

22.00.2026 - MRNA Stock was up 10.6%

• Moderna's bullish movement today could be attributed to positive sentiment surrounding the broader biotech sector and the company's ongoing efforts in vaccine development.
• The bullish market movement may also be influenced by the news of Bristol Myers partnering with Janux Therapeutics to develop novel tumor-activated therapeutics, highlighting the potential for innovative approaches in the healthcare industry.
• Additionally, the strong performance of other healthcare companies like Liquidia Technologies hitting an all-time high could have created a positive ripple effect in the sector, boosting investor confidence in Moderna's growth prospects.
• Overall, Moderna's bullish trend today seems to be driven by a combination of sector-wide optimism, positive developments in the healthcare industry, and potentially favorable market conditions for biotech companies.

22.00.2026 - MRNA Stock was up 12.0%

• The positive sentiment surrounding the efficacy and demand for Moderna's COVID-19 vaccine, as well as advancements in its pipeline for mRNA-based therapies, likely fueled the recent bullish movement.
• The collaboration between Janux Therapeutics and Bristol Myers Squibb could have played a role in boosting investor interest in biotech companies like Moderna.
• Abbott Laboratories' stock decline following revenue estimates miss may have indirectly benefited Moderna as investors potentially sought out companies with stronger growth potential.
• The selling of Merck & Co., Inc. shares by Bailard Inc. and other hedge funds may have shifted investments towards promising opportunities like Moderna, contributing to its bullish performance.

22.00.2026 - MRNA Stock was up 8.2%

• Moderna's stock surged by 4% following the groundbreaking five-year follow-up data for their mRNA cancer vaccine, showing a significant reduction in the risk of relapse or death in high-risk melanoma patients. This success not only boosted investor confidence in Moderna's technology but also solidified its position as a major player in oncology.
• The announcement of Moderna curbing investments in vaccine trials due to US backlash had a positive impact on the stock, with shares jumping by 10.16% in morning trading. This strategic shift towards personalized cancer treatments in response to regulatory hurdles demonstrates the company's adaptability and focus on long-term growth.
• The partnership between Bristol Myers Squibb and Janux Therapeutics in developing novel T cell engagers for solid tumors may have indirectly contributed to Moderna's bullish movement by highlighting the potential in oncology treatments, further fueling optimism in the biotech sector.
• Overall, Moderna's bullish market movement today can be attributed to its groundbreaking cancer vaccine data, strategic shift towards personalized treatments, and positive investor sentiment towards advancements in oncology therapies.